Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

NCT03028103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Primary Mediastinal Lymphoma
Mantle Cell Lymphoma
Advanced Solid Tumor
Marginal Zone Lymphoma

Interventions

DRUG: Tazemetostat
DRUG: Fluconazole
DRUG: Omeprazole
DRUG: Repaglinide

Sponsor

Epizyme, Inc.